Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Collaborates With DotBio to Discover Multi-Specific Antibodies

publication date: Jan 7, 2022

Shanghai Junshi Bio formed a collaboration with Singapore's DotBio to develop next-gen antibody therapies. Junshi in-licensed a DotBody module, which it will use to discover several multi-specific antibodies. DotBody's proprietary technology combines prefabricated antibody modules that have specific functions. DotBio says the technology builds multi-functional antibodies quickly, improving antibody quality and increasing their rate of success. DotBio will be receive upfront and milestone payments, as well as royalties. DotBio previously signed a licensing deal with Suzhou's CStone Pharma. More details....

Stock Symbols: (HK: 1877: SHA: 688180) (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.